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1. Introduction 
Remodeling during heart failure is characterized by structural rearrangement of the cardiac 
ventricular wall architecture. It involves hypertrophy of cardiomyocytes, fibroblast 
proliferation, and increased deposition of extracellular matrix (ECM) proteins (Brower et al., 
2006). Support of the left ventricle with a Left Ventricular Assist Device (LVAD) in patients 
with end-stage heart failure results in less neurohormonal activation (Estrada-Quintero et 
al., 1995; Frazier and Myers, 1999; Bruggink et al., 2006a), improvement of the patient’s 
general condition (De Jonge et al., 2001; Grady et al ., 2003), reduction in ventricular 
diameter (reverse remodeling), and limited recovery of contractile elements in 
cardiomyocytes (Muller et al., 1997; De Jonge et al., 2002). Furthermore, reduction of ECM 
volume (Milting et al., 2008; Goldsmith and Borg , 2002; Bruggink et al., 2006b), diminished 
production of tumor necrosis factor (Thohan et al., 2005; Bruggink et al., 2008), and 
reduction in brain natriuretic protein serum levels (Bruggink et al., 2006a; Kemperman et al., 
2004) have been described during LVAD support. The changes in ECM during this process 
of reverse remodeling resulted not only in a time-dependent change of type I and type III 
collagen protein (Goldsmith and Borg, 2002; Stamenkovic, 2003), but also in considerable 
changes in composition of the basal membrane. These included amongst others reduced 
collagen type IV content in the cardiomyocyte basal membrane, as a result of increased 
matrix metalloproteinase activity (Bruggink et al., 2007; Spinale, 2002; Li et al., 2001; Klotz et 
al., 2005). So, during LVAD support myocardial architecture and composition change at the 
level of both the cardiomyocytes and the ECM.  
The mechanics of the heart require a close interplay between cardiomyocytes and the ECM 
(Parker and Ingber, 2007) and therefore, one may anticipate a coordinated change in the 
molecules responsible for this interaction. These changes may not be the same in all heart 
failure patients supported by a mechanical support device. Some patients’ hearts may 
improve and may be eligible for removal of the support device without a heart 
transplantation (bridge to recovery and weaning from the device), whereas others do not 
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improve on support or may even deteriorate and these patients remain on the device 
(destination therapy) or will ultimately receive a heart transplant (bridge to transplantation). 
To make the proper choice of the type of therapy for each patient a good set of (bio)markers 
is required (De Weger and De Jonge, 2009). 
In this chapter, we describe whether mRNA expression patterns could be indicative for the 
state of heart functionality supported by a LVAD (Heart-Mate I, Thoratec, Pleasanton, CA, 
USA). The changes in mRNA profiles that are detectable in myocardial biopsies taken from 
patients with end-stage heart failure due to dilated cardiomyopathy (DCM) or ischaemic 
heart disease (IHD) before and after LVAD support were analyzed, and compared with 
biopsies taken from control hearts as a reference (Table 1). Furthermore, the expression of 
109 genes is described, which are involved in the process of mechanotransduction in the 
heart. Their expression was studied by Quantitative(Q)-PCR. The cohort comprised selected 
genes coding for ECM filaments (such as collagens), transmembrane proteins (molecules 
that connect cells and matrix components like integrins and sarcoglycans), intracellular 
molecules, adhesion molecules related to mechanotransduction and signal transduction, 
ion-channel molecules, and factors involved in pro- and anti-fibrotic processes. The 
expression of mRNA is not always directly related to protein production, due to post-
transcriptional regulation. Recently, it is has been shown that intracellular gene 
expression is regulated in part by small RNA molecules: microRNAs (miRs). These miRs 
are highly expressed in heart tissue (Ji et al., 2007; Cheng et al., 2007) and have also been 
related to heart diseases (Chen, 2007; Van Rooij et al., 2006). The list of regulatory miRs 
involved in heart disease is constantly increasing (Coutinho et al., 2007; Markham and 
Hill, 2010). Each miR can regulate various mRNA expressions and which mRNA is 
 
Nr Age Diagnosis Gender Days on LVAD Medication during  LVAD-support 
      
1 56 IHD  Male 138 None 
2 57 IHD Male 225 None 
3 45 IHD Male 259 2,5 mg Ramipril 
4 57 IHD Male 263 None 
5 36 IHD Male 325 2x 4 mg Perindopril 
6 26 IHD Male 357 None 
7 39 IHD Male 548 3x 6,25 mg Capoten 
8 34 DCM Female 55 3x 6,25 mg Capoten 
9 17 DCM Male 111 None 
10 47 DCM Male 190 None 
11 35 DCM Male 196 None 
12 32 DCM Female 219 3 mg Captopril 
13 25 DCM Male 263 1x 25 mg Losartan 
14 32 DCM Male 286 4 mg Perindopril 
15 25 DCM Male 330 2x 10 mg Fosinopril 
16 46 DCM Male 484 3x 50 mg Capoten 
DCM: dilated cardiomyopathy, IHD: ischemic heart disease, LVAD: left ventricular assist device. 
Table 1. Patient characteristics. 
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regulated by which miR is not determined with certainty for most genes (see 
www.targetscan.org; Schuldt, 2010). 
An additional goal of this study was therefore, to analyse the changes in expression of 4 
miRs that are known to be expressed in the myocardium (Chen, 2007; Ikeda et al., 2007): 
miR-1, miR-133a, miR-133b and miR-208. These miRs have been related to heart failure.  The 
expression of these miRs was measured in the same group of patients used to analyse the 
mRNA expression after LVAD support. Our purpose was to find out whether the LVAD-
induced remodeling of the heart was accompanied by changes in the expression of miRs 
that could influence the protein expression of the mRNA studied. This could make 
expression of some mRNAs less suitable as biomarker for the assessment of the functional 
quality of the supported heart. If this is the case the expression of miRs may serve as better 
markers either in the myocardium or the serum. 
2. Tissue distribution of mRNA and miR in the myocardium 
Tissue samples taken form various locations in cross sections of the heart showed that the 
expression of both miR in the right and left ventricular wall did not show significant 
variation. Only in the infarcted area the expression of miR was low to absent. Similar data 
were obtained for mRNA (Figure 1). 
 
 
Fig. 1A. Circular cross section of the heart indicating the biopsy areas. 
B and C. miRNA expression in and around the infarcted area in the indicated biopsies of a 
representative case. The miRNA expression in an infarcted area (biopsy 4) is much lower 
than in the surrounding areas. LV and RV = left and right ventricle. 
3. Hierarchical clustering of gene expression in myocardial tissue of IHD and 
DCM patients 
The gene profiles in DCM and IHD heart tissue, detected by Q-PCR, were compared using 
TIGR software (www.tm4.org). Figure 2 shows the whole data set for all pre-LVAD samples 
versus the median of control samples. Hierarchical clustering was performed on all 92 
detectable genes. The genes that were not detectable (n=14) and house keeping genes (n=3) 
were excluded (Table 2). The clustering segregated two groups: one group consists of 6 
DCM and 1 IHD patients and the other group consists of 5 IHD patients with 2 DCM 
patients. One DCM and one IHD patient were clustered outside both groups. So, there is a 
strong tendency of segregation between IHD and DCM. Therefore, the DCM and IHD 
patient groups were analyzed separately in this study. 
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Fig. 2. Unsupervised hierachical clustering of myocardial gene expression profiles 
pre-LVAD in IHD and DCM patients. Clustering was performed on all 92 detectable genes. 
Unsupervised hierarchical clustering was performed on normalized data using the multi-
experiment viewer (MeV, version 4.3) of the TIGR software (www.tm4.org). The Reletive 
quantity (RQ) of each sample per gene was normalized:  
Normalized signal of sample x = Log2 (RQ sample x / median RQ). 
To compare DCM and IHD the median was taken from the RQ (relative quality) of control 
hearts. To compare pre- and post-LVAD in DCM and IHD samples, the median of all DCM 
or all IHD samples were taken, respectively. Clustering was performed on the whole 
dataset, and distance metric selection (Euclidean distance) and linkage metric selection 
(Complete linkage clustering) were used (www.tm4.org). This segregated two groups; one 
group consisting of 6 DCM patients with 1 IHD patient, and the other of 5 IHD patients with 
2 DCM patients. Two patients (one DCM and one IHD) clustered outside these groups. Red: 
mRNA expression is higher than the median of control hearts. Green: mRNA expression is 
lower than the median of control hearts. Grey: not done. 
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Fig. 3. Unsupervised hierarchical clustering of myocardial gene expression profiles pre- and 
post-LVAD in IHD patients.  
Clustering was performed on all 92 detectable genes and it segregated the patient group into 
a pre- and post-LVAD group. See for explanation Figure 2. Red: mRNA expression is higher 
than the median of all IHD samples. Green: mRNA expression is lower than the median of 
all IHD samples. Grey: not done.  
 
The expression of 14 genes was below level of detection and are therefore not included in 
this table: ADAM 12 (ADAM metallopeptidase domain 12), ADAM 15 (ADAM 
metallopeptidase domain 15), AGC1 (aggrecan 1), ANK1 (Ankyrin 1), DSPG3 (dermatan 
sulfate proteoglycan 3), EDN3 (endothelin 3), LAMC3 (laminin, gamma 3), MMP-7 (matrix 
metallopeptidase 7), MUC16 (mucin 16), NOS1 (nitric oxide synthase 1), SCN1A (sodium 
channel, voltage-gated, type I, alpha), SCN2A2 (sodium channel, voltage-gated, type II, 
alpha 2), SDC1 (syndecan 1), TNXB (tenascin XB). 
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Table 2. Statistical analysis of gene expression profiles in DCM and IHD patients. 
Significant changes are indicated in yellow. The genes are grouped by function/location. 
Abbreviations: extracellular matrix proteins (ECM), pro- and anti-fibrotic factors (P/AFF), 
basal membrane proteins (BM), transmembrane and adhesion molecules (TAM), 
intracellular filaments (IF), and signal transduction factors (STF). Applied Biosystems (AB). 
> and < indicate whether gene expression is significantly higher or lower compared to 
control.  
4. Hierarchical clustering of gene expression in myocardial tissue pre- and 
post-LVAD support 
Hierarchical clustering of the IHD samples showed a clear segregation into a pre- and a 
post-LVAD group (Figure 3). In DCM patients a similar segregation into a pre- and a post-
LVAD group was not evident (data not shown). 
5. Differential expression of genes in myocardial tissue pre- and post LVAD 
Changes in gene expression were tested individually using the paired t-test in DCM and 
IHD separately. Furthermore, these gene profiles were compared with gene profiles of 
controls to test whether gene profiles normalized or showed a tendency to deviate from 
normal after LVAD therapy using the unpaired t-test. Table 2 shows all genes investigated, 
grouped by function/ location: extracellular matrix proteins (ECM), basal membrane 
proteins (BM), transmembrane and adhesion molecules (TAM), intracellular filaments (IF), 
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signal transduction factors (STF) and pro- and anti-fibrotic factors (P/AFF) with the p-
values and fold changes. 
In Table 3 only the genes that show significant changes are indicated for DCM and IHD 
patients separately. Only a minority of genes showed a significant difference between pre- 
and post-LVAD: DCM 19/92 genes (21 %) and IHD 12/92 genes (13 %). Most of these genes 
showed an upregulation post-LVAD (DCM 18/19 genes and IHD 8/12 genes). In DCM pre-
LVAD 6 genes and post-LVAD 9 genes were upregulated compared to control. Only one 
gene, encoding caveolin, showed a decreased expression in both pre- and post-LVAD 
compared to control. In IHD pre-LVAD 12 genes were upregulated and 2 downregulated 
compared to control. Post-LVAD 6 were upregulated and 2 downregulated. Among these, 
two genes (dystrophin and laminin gamma 1) showed an increased expression compared to 
control in both pre- and post-LVAD samples. 
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osteopontin ▼ = < fibronectin 1 ▼ > =
bone morphogenetic protein 4 ▲ = > integrin, alpha 5 ▼ = =
collagen, type VI, alpha 3 ▲ = > osteopontin ▼ = =
filamin B, beta ▲ = > sarcoglycan, beta ▼ = =
laminin, gamma 1 ▲ = > ryanodine receptor 2 (cardiac) ▲ = >
ryanodine receptor 2 (cardiac) ▲ = > cadherin 13, H-cadherin (heart) ▲ = =
talin 2 ▲ = > calcium channel, alpha 1C subunit ▲ = =
cadherin 13, H-cadherin (heart) ▲ = = catenin (cadherin-associated protein), alpha 3 ▲ = =
calcium channel, alpha 1C subunit ▲ = = desmoplakin ▲ = =
collagen, type XIV, alpha 1 ▲ = = integrin, alpha 6 ▲ = =
collagen, type XV, alpha 1 ▲ = = integrin, beta 6 ▲ = =
decorin ▲ = = myocyte enhancer factor 2A ▲ = =
focal adhesion kinase ▲ = = myocyte enhancer factor 2C ▲ = =
heparan sulfate proteoglycan 2 (perlecan) ▲ = = spectrin alpha ▲ = =
inhibitor of DNA binding 1 ▲ = = ATPase, Ca++ transporting, cardiac muscle ▲ < =
integrin, alpha 1 ▲ = = dystrophin = > >
integrin, alpha 10 ▲ = = lamin, gamma 1 = > >
laminin, beta 1 ▲ = = bone morphogenetic protein 4 = > =
bone morphogenetic protein 7 ▲ < = collagen, type XIV, alpha 1 = > =
integrin, alpha 6 ▲ < = connective tissue growth factor = > =
dystrobrevin beta = > = fibromodulin = > =
vitronectin = > = insulin-like growth factor 1 = > =
integrin, alpha 11 = = > integrin, beta 5 = > =
sarcoglycan, beta = = < integrin, alpha 10 = > =
fibroblast growth factor 2 = < = integrin, alpha 6 = > =
junction plakoglobin = < = osteonectin = > =
caveolin 1 = < < thrombospondin 2 = > =
integrin, alpha 11 = = >
laminin, alpha 2 = = >
sarcoglycan, delta = = >
talin 1 = = >
mothers against DPP homolog 6 = = <
bone morphogenetic protein 7 = < =  
 
 
Table 3. Summary of significant alterations in gene expression.  
▼: decreased or ▲: increased gene expression after LVAD support, =: no change, >:higher 
or <:lower expression pre- or post-LVAD compared to control. The shaded (green) genes are 
significantly altered in both DCM and IHD. 
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Fig. 4. Relative mRNA expression of genes encoding ECM proteins.  
Relative mRNA expression was determined pre- and post-LVAD of DCM and IHD and 
tested in paired t-test. Increase of collagen 14ǂ1 mRNA expression is significant in DCM but 
not in IHD. Compared to the control, only the mRNA expression pre-LVAD of IHD patients 
is significantly higher (unpaired t-test). Decorin is significantly increased post-LVAD in 
DCM. None of the pre- and post-LVAD samples differed significantly from the control 
samples.  
5.1 Genes encoding extracellular matrix proteins 
In DCM, 5 genes encoding ECM proteins were upregulated post-LVAD. However, except 
for collagen type VI alpha3, these genes did not differ significantly (either pre- or post 
LVAD) from control. This indicates that the increased expression of these 5 genes induced 
by the LVAD support is significant but as a group are not different from the control group 
(Figure 4). In IHD most differences between pre-LVAD and control were observed in genes 
encoding ECM proteins, but in post-LVAD samples these differences had disappeared, 
suggesting a high expression of ECM gene activity pre-LVAD (Figure 4).  
Relative mRNA expression was determined pre- and post-LVAD of DCM and IHD and 
tested with the paired t-test. Increase of integrin ǂ6 mRNA expression was significant in 
both DCM and IHD during LVAD support. Compared to the control, only the mRNA 
expression pre-LVAD of DCM patients is significantly lower (unpaired t-test). Integrin ǃ6 is 
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only significantly increased post-LVAD in the IHD group. Compared to the control none of 
the pre- and post-LVAD samples differed significantly.  
 
 
Fig. 5. Relative mRNA expression of genes encoding different integrins. 
5.2 Genes involved in the fibrotic pathway 
In the fibrotic pathway remarkable differences between DCM and IHD were observed. In 
DCM patients the expression of genes encoding pro-fibrotic factors (TGFǃ1, FGF, IGF, 
endothelin and CTGF) remained unchanged, whereas the genes encoding anti-fibrotic  
proteins (BMP-4, BMP-7, decorin and ID1) increased after LVAD support. Pre-LVAD the 
expression of the pro-fibrotic factor FGF2 and the anti-fibrotic factor BMP-7 was low 
compared to control. Post-LVAD the expression of the anti-fibrotic factor BMP-4 was 
increased compared to control. However, in IHD patients these genes showed unchanged 
expression during LVAD support, but in pre-LVAD samples the pro-fibrotic genes are 
expressed stronger than in control and the anti-fibrotic gene BMP-7 is expressed less than in 
control. The post-LVAD expression pattern is comparable to that of control.  
5.3 Genes encoding basal membrane proteins 
The gene encoding osteopontin is the most remarkable member of the BM group. In both 
DCM and IHD patients, osteopontin expression is significantly reduced after LVAD 
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support. Other BM proteins showed hardly any change, apart from laminin, vitronectin and 
thrombospondin (anchoring proteins). 
Several integrins showed differential expression (mostly upregulation) in both DCM and 
IHD patients. In particular, integrin ǃ6 gene expression showed a strong increase after 
LVAD in the IHD group (Figure 5). Other membrane molecules, like caveolin, sarcoglycan 
and ATPase calcium transporting molecule, showed a low expression compared to control 
either pre- or post-LVAD. 
5.4 Genes encoding intracellular proteins 
Expression of some intracellular filament genes changed significantly after LVAD support in 
DCM (2/19: filamin, talin) and in IHD (1/19:desmoplakin), suggesting only a minor 
intracellular filament involvement. In this group it was remarkable that in IHD the gene 
encoding dystrophin was upregulated both pre- and post-LVAD.  
Relatively many changes in the expression of signal transduction factors were observed after 
LVAD support both in DCM (2/8: Focal Adhesion Kinase and Ryanodine Receptor 2) and in 
IHD (4/8: catenin, myocyte enhancer factor 2A and 2C, and Ryanodine Receptor 2). 
6. Changes in miR expression during LVAD support 
Total RNA was isolated from heart tissue of heart failure patients pre- and post-LVAD. The 
relative quantities of miRNA1, miRNA133a, miRNA133b and miRNA-208 were established 
with the Taqman® MicroRNA assay (Applied Biosystems, Foster City, CA, USA). In Figure 
6 the expression of miR-1, miR-133a and of miR133b is shown for DCM and IHD patients 
pre- and post-LVAD. Compared to control levels the miR expression in both heart failure 
groups was low for all miR tested. These low levels were more significant in IHD than in 
DCM.  After LVAD support the levels did not change significantly, although in IHD there 
was a tendency that the miR expression levels return to normal. In patients with DCM we 
observed a tendency of further decrease. The expression of miR-208 showed similar changes 
(data not shown) as did the other three miRs. However, the expression was too low to make 
a reliable statistical analysis. 
 
 
 
Fig. 6. Changes in miR expression after LVAD support 
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miR DCM-patients IHD-patients 
 1 2 3 1 2 3 
miR-1 0.20 0.24 0.06 0.08 0.05 0.44 
miR-133a 0.73 0.19 0.04 0.11 0.07 0.35 
miR-133b 0.02 0.44 0.04 0.11 0.09 0.44 
Table 4. Statistical analysis of miR expression changes after LVAD support. 
The relative quantities of miR-1, miR-133a  and miR-133b measured in heart tissue obtained 
from patients suffering from IHD ( n= 8) or DCM (n=9) or C: controls (n=5; Pre = pre LVAD 
support ; Post= post LVAD support. 
The p-values for the various differences in relative quantitative expression of the miRs in the 
myocardium obtained from DCM and IHD patients, respectively, before and after LVAD 
support. P< 0.05 is considered significant. 
1: pre-LVAD versus post LVAD;  2: pre-LVAD versus control; 3: post LVAD versus control. 
The results of the statistical analyses are presented in Table 4. These data confirm that in 
DCM patients, LVAD support did not increase the low miR-expression. In patients with 
IHD the values of expression of the miRs after LVAD support were not significantly 
different from those in the controls, indicating that there was a tendency of the low levels of 
miRs to increase after LVAD in IHD patients. 
7. Discussion 
During unloading, the myocardium of the failing heart shows various changes, both 
macroscopically and microscopically. Major changes include reduction of cardiomyocyte 
size, and changes in the volumes of ECM and BM components (Goldsmith and Borg, 202; 
Bruggink et al., 2006; Parker and Ingber, 2007). In many studies analyzing the effect of 
mechanical support on heart failure, only marginal differences have been observed between 
IHD and DCM (Bruggink et al., 2006a; De Jonge et al., 2001, 2002; Grady et al., 2003). 
However, in the present study hierarchical clustering of all expressed genes in end-stage 
heart failure showed that DCM and IHD segregated and could be identified as separated 
entities (Figure 2). For this reason both groups were analyzed separately. In the IHD group 
pre- and post-LVAD samples did segregate by hierarchical clustering (Figure 3). In the DCM 
group no such separation of pre- and post-LVAD samples was observed. The explanation 
for this difference between both groups is unknown. DCM may have a genetic background 
that leads primarily to hypertrophy and fibrosis, leading to gene expression that differs 
from controls in several aspects, but is not completely reversed by LVAD support. By 
contrast, in IHD, the gene expression alterations that are induced by infarction are partly 
normalized by the unloading of the heart. The differences in mRNA expression between 
IHD and DCM may give an important clue in finding targets that are informative for the 
state of the (un)supported hearts. 
In pre-LVAD samples of DCM patients, the expression of only 7 genes (2 up- and 5 
downregulated) differed from control which increased to 10 genes post-LVAD (7 up- and 3 
down-regulated). In IHD pre-LVAD samples, the expression of 15 genes (13 up- and 2 down-
regulated) differed from control, which decreased to 8 genes post-LVAD (7 up- and only 1 
down-regulated). In both groups most genes that were differentially expressed pre-LVAD 
normalized to control levels after LVAD support. On the other hand, LVAD support can also 
induce a down- or upregulation of genes of which the pre-LVAD levels did not differ from 
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control level (Table 2). Eleven genes showed significant changes pre- and post-LVAD in both 
DCM and IHD. However, only 3 genes showed changes that were the same in DCM and IHD 
(calcium channel alpha 1C subunit, integrin-ǂ11 and ryanodine receptor 2).  
In DCM, the expression of caveolin remained low (both pre- and post-LVAD) compared to 
control. This is in contrast to the described up-regulation of caveolin protein after LVAD 
support (Uray et al., 2003). In IHD the expression of dystrophin and laminin (gamma 1) 
remained high after LVAD support. Changes in expression of both genes after LVAD have 
been described by others (Vatta et al., 2004; Birks et al., 2005; Refaat et al., 2008). 
LVAD-induced changes in ECM and cardiomyocytes have been described by others as well 
(Milting et al., 2008; Bruggink et al 2006b; Thohan et al., 2005). In this respect, the total 
number of genes coding for various structural elements, that were differentially expressed 
pre- and post-LVAD was surprisingly low. Morphological changes during LVAD support 
were paralleled by changes in collagen turnover and expression of genes encoding for 
structural collagens (Type I and III; Bruggink et al, 2006b; 2007). So, the minor changes 
observed in expression of ECM genes in the present study may imply that most ECM 
changes are induced post-transcriptionally, either by micro-RNA regulation (Schipper et al., 
2008) or in the matrix itself (e.g. by MMP). The latter is supported by significant changes in 
mRNA expression of MMP during LVAD support (Li et al., 2001; Klotz et al., 2005). 
Interestingly the anchoring and connecting collagens (types VI, XIV and XV) and molecules 
involved in ECM assembly like fibulin, fibronectin, osteonectin and proteoglycans 
(fibromodulin, heparan sulfate and decorin; Pollard et al., 2008) changed upon LVAD, 
although not similar in DCM and IHD patients. The LVAD-induced changes in the 
expression of these molecules, including collagen, also observed by others (Jahanyar et al., 
2007; Gabrielsen et al., 2007), may contribute to the increased rigidity of the heart after 
LVAD support (Klotz et al., 2005). 
Previously, we have shown that unloading of the left ventricle decreased the 
immunohistochemical expression of collagen IV in the BM (Bruggink et al., 2007). In 
contrast, immunoreactivity of laminin did not show substantial changes upon LVAD. Of the 
17 tested genes that encode BM proteins only few showed expression changes after LVAD, 
indicating a dysbalance between mRNA expression and protein expression. The few genes 
that did show changes upon LVAD, either in DCM or IHD, are involved in cell-adhesion 
(laminin ǃ1 and Ǆ1, osteopontin). Together with the changes observed in the gene 
expression of the integrin, cadherin and sarcoglycan family members, these results 
underline the importance of these specific anchoring or connecting proteins in the structural 
changes observed (Birks et al.,2005; Gabrielsen et al., 2007; Latif et al., 2007; Kim et al.,1999).  
Only minor changes were observed in the expression of genes encoding intracellular 
cytoskeleton proteins. In DCM, alterations after LVAD support in cytoskeletal filaments 
(dystrobrevin, filamin, junction plakoglobin, and talin) are more pronounced than in IHD 
(desmoplakin, dystrophin and talin; Gabrielsen et al., 2007). This could indicate that this 
class of genes is more affected in DCM than in IHD, which may be explained by the 
different onset of myocardial damage in both diseases. 
In the fibrotic pathway a remarkable difference between DCM and IHD is observed. In 
DCM the expression of pro-fibrotic factors (TGFǃ1, FGF, IGF, endothelin and CTGF) did not 
change upon LVAD support, but the expression of anti-fibrotic genes (BMP-4, BMP-7, 
decorin, and Id1) increased. This is paralleled by reduced fibrosis in DCM (Bruggink et al., 
2006b).  In patients with IHD the expression of both anti- and pro-fibrotic factors remain 
unchanged upon LVAD support. However, in IHD the pre-LVAD expression levels of the 
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pro-fibrotic response genes are stronger than in control whereas the expression of the anti-
fibrotic gene BMP-7 is lower than in control. This will favour fibrosis in the hearts of 
patients with IHD. In these patients, the post-LVAD situation may be associated with a 
return of gene expression to control values. This may lead to a reduction of fibrosis as is 
shown in various studies. So, pro- and anti-fibrotic gene expression is in agreement with 
previously described reduction of fibrosis after LVAD support (Goldsmith and Borg, 2002; 
Gabrielsen et al., 2007), although the mechanisms responsible differed between the two 
entities. 
In view of the changes in mRNA expression that did not seem to be paralleled by 
corresponding protein expression, special emphasis was given to miR expression during 
LVAD support. These miRs are important in the post-transcriptional regulation of mRNAs, 
also in the heart (Chen, 2007; Couzin, 2008). The miRs tested (miR-1, miR-133a and 
miR133b) had relatively low expression in the myocardium of heart failure patients 
compared to controls. In IHD patients the level of miR expression tended to return to 
control levels upon LVAD support. In DCM, however, the miR expression levels tended to 
decrease even further, which suggests that genes under the control of these miRs could be 
expressed even stronger. Chen et al. (2006) have described that miR-1 and miR-133 promote 
skeletal muscle myogenesis and myoblast proliferation, respectively (Townley-Tilson et al, 
2010). Similar data have been produced by Liu et al. (2007) and Ikeda et al. (2008) for the 
failing myocardium. The relatively low expression of miRs in the failing heart, compared to 
control, may be related to the presence of myocardial hypertrophy (De Jonge et al., 2002), as 
overexpression of both miR-1 and miR-133 leads to cardiac hypertrophy (Care et al., 2007).  
This difference in miR expression between DCM and IHD patients after LVAD support may 
be explained by the lack of need for cell proliferation in DCM unlike in IHD where there is a 
need for cell proliferation. Remodeling of DCM involves mainly a reduction of hypertrophy 
of cardiomyocytes, whereas IHD involves tissue repair including cell proliferation. This may 
indicate that the studied miRs are primarily involved in regulation of proliferative processes 
rather than in reduction of hypertrophy. As already mentioned, the reduction in miRNA 
expression in IHD patients is not restored completely to control levels during LVAD 
support, not in patients supported for a short period of time nor in patients supported for 
more than over one year.  
The miR data do show that myocardial expression of miRs changes upon heart failure (Busk 
and Cirera, 2010) and upon LVAD support. In that respect it is interesting to note that there 
are initial indications that miR released in the serum (Cheng et al. 2010) may act as 
biomarkers to screen for cardiac diseases (Adachi et al., 2010) and be targets for therapy 
(Seok and Wang, 2010). 
In conclusion, the set of genes coding for proteins involved in mechanotransduction, 
selected for the analysis of changes in mRNA expression pre- and post-LVAD, resulted in an 
identification of IHD and DCM as separate entities. The morphologic and structural changes 
observed in the failing human heart upon LVAD support are only partly reflected in 
changes of mRNA expression of genes encoding proteins involved in mechanotransduction. 
This suggests that most changes in ECM and intracellular filaments are not regulated at the 
mRNA level. However, expression of genes encoding membrane-bound proteins such as 
cadherin and integrins, and anchoring proteins such as collagen type VI and proteoglycans, 
is clearly affected by LVAD support and contributes to adaptation to improved loading 
conditions. Also the genes involved in fibrosis showed adaptation to LVAD support, and 
their expression runs parallel to the observed morphological changes. These genes may 
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prove to be important biomarkers in the development of protocols which decide whether 
LVAD supported patients should undergo heart transplantation, can be weaned from the 
device, or could rather continue their LVAD therapy for a longer period of time. The role of 
miR as biomarkers in this decision making, but also as therapeutic targets, is promising but 
still needs further investigation (Montgomery and van Rooij, 2010). 
8. Acknowledgement 
MFM van Oosterhout was supported by a grant from the Dutch Heart Foundation; project 
number 2004T31. 
9. References  
Adachi , T.; Nakanishi, M.; Otsuka, Y.; Nishimura, K.; Hirokawa, G.; Goto, Y.; Nonogi, H. & 
Iwai, N. (2010). Plasma microRNA 499 as a biomarker of acute myocardial 
infarction. Clin Chem 56(7), 1183-1185. 
Birks, E.J.; Hall, J.L.; Barton, P.J.R.; Grindle, S.; Latif, N.; Hardy, J.P.; Rider, J.E.; Banner, N.R.; 
Khaghani, A.; Miller, L.W. & Yacoub, M.H. (2005). Gene profiling changes in 
cytoskeletal proteins during clinical recovery after left ventricular-assist device 
support. Circulation 112(9), 157-164. 
Brower, G.L.; Gardner, J.D.; Forman, M.F.; Murray, D.B.; Voloshenyuk, T.; Levick, 
S.P.;.Janicki, J.S. (2006) The relationship between myocardial extracellular matrix 
remodeling and ventricular function. Eur J Cardiothorac Surg 30(4), 604-610. 
Bruggink, A.H.; de Jonge, N.; van Oosterhout, M.F.; Van Wichen, D.F.; de Koning, E.; 
Lahpor, J.R.; Kemperman, H.; Gmelig-Meyling, F.H.J. & de Weger, R.A. (2006a). 
Brain natriuretic peptide is produced both by cardiomyocytes and cells infiltrating 
the heart in patients with severe heart failure supported by a left ventricular assist 
device. J Heart Lung Transplant 25(2), 174-80. 
Bruggink, A.H.; van Oosterhout, M.F.; de Jonge, N.; Ivangh, B.; Van Kuik, J.; Voorbij, 
R.H.A.M.; Cleutjens, J.P.M.; Gmelig-Meyling, F.H.J. & de Weger, R.A. (2006b). 
Reverse remodeling of the myocardial extracellular matrix after prolonged left 
ventricular assist device support follows a biphasic pattern. J Heart Lung Transplant 
25(9), 1091-1098.  
Bruggink, A.H.; van Oosterhout, M.F.M.; de Jonge, N.; Cleutjens, J.P.M.; Van Wichen, D.F.; 
van Kuik, J.; Tilanus, M.G.J.; Gmelig-Meyling, F.H.J.; van den Tweel, J.G.; De 
Weger, R.A. (2007). Type IV collagen degradation in the myocardial basement 
membrane after unloading of the failing heart by a left ventricular assist device. Lab 
Invest 87(11), 1125-1137. 
Bruggink, A.H.; van Oosterhout, M.F.; De Jonge, N.; Gmelig-Meyling, F.H.; De Weger, R.A. 
(2008). TNF alpha in patients with end-stage heart failure on medical therapy or 
supported by a left ventricular assist device. Transpl Immunol 19(1), 64-68. 
Busk, P.K. & Cirera, S. (2010). MicroRNA profiling in early hypertrophic growth of the left 
ventricle in rats. Biochem Biophys Res Commun  396(4), 989-993. 
Carè, A.; Catalucci, D.; Felicetti, F.; Bonci, D.; Addario, A.; Gallo, P.; Bang, M.-L.; Segnalini, 
P.; Gu Y.S.; Dalton, N.D.; Elia, L.; Latronico, M.V.G.; Hoydal, M.; Autore, C.; Russo, 
M.A.; Dorn, G.W.; Ellingsen, O.; Ruiz-Lozano, P.; Peterson, K.L.; Croce, C.M.; 
www.intechopen.com
 Ventricular Assist Devices 
 
64 
Peschle, C. & Condorelli, G. (2007). MicroRNA-133 controls cardiac hypertrophy. 
Nat Med 13(5), 613-618. 
Chen, J.F.; Mandel, E.M.; Thomson, J.M.; Wu, Q.L.; Callis, T.E.; Hammond, S.M.; Conlon, 
F.L. & Wang, D.Z. (2006). The role of microRNA-133 in skeletal muscle proliferation 
and differentiation. Nat Genet 38(2), 228-233. 
Chen, K.R. (2007). MicroRNAs and the tell-tale heart. Nature 447(7144), 389-922. 
Cheng, Y.; Ji, R.; Yue, J.; Yang, J.; Liu, X.; Chen, H.; Dean, D.B. & Zhang, C. (2007). 
MicroRNAs Are Aberrantly Expressed in Hypertrophic Heart: Do They Play a Role 
in Cardiac Hypertrophy? Am J Pathol 170 (4), 1831-1840. 
Cheng, Y.H.; Tan, N.; Yang, J.A.; Liu, X.J.; Cao, X.P.; He, P.C.; Dong, X.L.; Qin, S.S & Zang, 
C.X. (2010). A translational study of circulating cell-free miRNA-1 in acuite 
myocardial infarction. Clin Sc 119 (1-2), 87-95. 
Coutinho, L.L.; Matukumalli, L.K.; Sonstergard, T.S.; Van Tassell, C.P.; Gasbarre, L.C.; 
Capuco, A.V. & Smith, T.P.L. (2007). Discovery and profiling of bovine microRNAs 
from immune-related and embryonic tissues. Physiol Genomics 29(1), 35-43. 
Couzin, J.  (2008). MicroRNAs make big impression in disease after disease. Science 
319(5871), 1782-1784. 
De Jonge,  N.; Kirkels, H.; Lahpor, J.R.; Klopping, C.; Hulzebos, E.J.; de la Riviere, A.B. & de 
Medina, E.O.R. (2001). Exercise performance in patients with end stage heart failure 
after implantation of a left ventricular assist device and after heart transplantation: 
an outlook for permanent assisting? J Am Coll Cardiol 37(7), 1794-1799. 
De Jonge, N.; Van Wichen, D.F.; Schipper, M.E.; Lahpor, J.R.; Gmelig-Meyling, F.H.J.; de 
Medina, E.O. & De Weger, R.A. (2002). Left ventricular assist device in end-stage 
heart failure: persistence of structural myocyte damage after unloading. An 
immunohistochemical analysis of the contractile myofilaments. J Am Coll Cardiol 
39(6),963-969. 
De Weger, R. & De Jonge, N. (2009). Editorial comment heart transplantation. Curr Opin 
Organ Transplant 14(5), 552-553. 
Estrada-Quintero, T.; Uretsky, B.F.; Murali, S.; Griffith, B.P. & Kormos, R.L. (1995). 
Neurohormonal activation and exercise function in patients with severe heart 
failure and patients with left ventricular assist system. A comparative study. Chest 
107(6), 1499-1503. 
Frazier, O.H. & Myers, T.J. (1999). Left ventricular assist system as a bridge to myocardial 
recovery. Ann Thorac Surg 68(2), 734-41.  
Gabrielsen, A. ; Lawler, P.R. ; Wang, Y.Z. ; Steinbruchel, D.; Blagoja, D.; Paulsson-Berne, G.; 
Kastrup, J. & Hansson, G.K. (2007). Gene expression signals involved in ischemic 
injury, extracellular matrix composition and fibrosis defined by global mRNA 
profiling of the human left ventricular myocardium. J Mol Cell Cardiol 42(4), 870-
883. 
Goldsmith, E.C. & Borg, T.K. (2002). The dynamic interaction of the extracellular matrix in 
cardiac remodeling. J Card Fail 8(6), S314-S318. 
Grady, K.L.; Meyer, P.M.; Mattea, A.; Dressler, D.; Ormaza, S.; White-Williams, C.; Chillcott, 
S.; Kaan, A.; Loo, A.; Todd, B.; Klemme, A.; Piccione, W. & Costanzo, M.R. (2003). 
Change in quality of life from before to after discharge following left ventricular 
assist device implantation. J Heart Lung Transplant 22(3) 322-333. 
www.intechopen.com
Altered Expression of mRNA and miRNA during Mechanical Support of the Failing Human Heart   
 
65 
Ikeda, S.; Kong, S.W.; Lu, J.; Bisping, E.; Zhang, H.; Allen, P.D.; Golub, T.R.; Pieske, B. & Pu, 
W.T. (2007). Altered microRNA expression in human heart disease. Physiol Genom 
31(3), 367-373. 
Jahanyar, J. ; Joyce, D.L. ; Southard, R.E. ; Loebe, M.; Noon, G.P.; Koerner, M.M.; Torre-
Amione, G.& Youker, K.A. (2007). Decorin-mediated transforming growth factor-
beta inhibition ameliorates adverse cardiac remodeling. J Heart Lung Transplant 
26(1), 34-40. 
Ji, R.R.; Cheng,Y.H.; Yue, J.M.; Yang, J.; Liu, X.; Chen, H.; Dean, D.B. & Zhang, C.X. (2007). 
croRNA expression signature and antisense-mediated depletion reveal an essential 
role for microRNA in vascular neointimal lesion formation. Circ Res 100(11), 1579-
1588. 
Kemperman, H.; van den Berg, M.; Kirkels,  H. & De Jonge, N. (2004). B-type natriuretic 
peptide (BNP) and N-terminal proBNP in patients with end-stage heart failure 
supported by a left ventricular assist device. Clin Chem 50(9), 1670-1672. 
Kim, H.; Yoon, C.S. & Rah, B. (1999). Expression of extracellular matrix components 
fibronectin and laminin in the human fetal heart. Cell Struct Funct 24(1), 19-26. 
Klotz, S.; Foronjy, R.F.; Dickstein, M.L.;Garrelds, I.M.; Danser, A.H.J.; Oz, M.C.; D'Armiento, 
J. & Burkhoff, D. (2005). Mechanical unloading during left ventricular assist device 
support increases left ventricular collagen cross-linking and myocardial stiffness. 
Circulation 112(3), 364-374. 
Latif, N.; Yacoub, M.H.; George, R.; Barton, P.J. & Birks EJ. (2007). Changes in sarcomeric 
and non-sarcomeric cytoskeletal proteins and focal adhesion molecules during 
clinical myocardial recovery after left ventricular assist device support. J Heart Lung 
Transplant  26(3), 230-235. 
Li, Y.Y. ; Feng, Y.Q.; McTiernan, C.F. ; Moravec, C.S.; Wang, P.; Rosenblum, W.; Kormos, 
R.L. & Feldman, A.M. (2001). Downregulation of matrix metalloproteinases and 
reduction in collagen damage in the failing human heart after support with left 
ventricular assist devices. Circulation 104(10), 1147-1152. 
Liu, N.; Williams, A.H.; Kim, Y.; McAnally, J.; Bezprozvannaya, S.; Sutherland, L.B.; 
Richardson, J.A.; Bassel-Duby, R. & Olson, E.N. (2007). An intragenic MEF-2 
dependent enhancer directs muscle-specific expression of microRNAs 1 and 133. 
Proc Nat Acad Sci USA 104(52), 20844-20849. 
Markham, D.W. & Hill, J.A. (2010). MicroRNAs and heart failure diagnosis: MiR-acle or 
MiR-age?. Circ Res 106 (4), 1011-1013. 
Milting, H.; Ellinghaus, P.; Seewald, M.; Cakar, H.; Bohms, B.; Kassner, A.; Koerfer, R.; 
Klein, M.; Krahn, T.; Kruska, L.; El Banayosy, A.. & Kramer, F. (2008). Plasma 
biomarkers of myocardial fibrosis and remodeling in terminal heart failure patients 
supported by mechanical circulatory support devices. J Heart Lung Transplant 27(6), 
589-596. 
Montgomery, R.L. & Van Rooij, E (2010). MicroRNA regulation as a therapeutic strategy for 
cardiovascular disease. Curr Drug Targets 11 (8), 936-942. 
Muller, J.; Wallukat, G.; Weng, Y.G.; Dandel, M.; Spiegelsberger, S.; Semrau, S.; Brandes, K.; 
Theodoridis, V.; Loebe, M.; Meyer, R. & Hetzer, R. (1997). Weaning from 
mechanical cardiac support in patients with idiopathic dilated cardiomyopathy. 
Circulation 96(2), 542-549. 
www.intechopen.com
 Ventricular Assist Devices 
 
66 
Parker, K.K. & Ingber, D.E. (2007). Extracellular matrix, mechanotransduction and structural 
hierarchies in heart tissue engineering. Philos Trans R Soc Lond B Biol Sci. 362(1484), 
1267-1279. 
Pollard, T.D. & Earnshaw, W.C. (2008). Section VIII Cellular adhesion and the extracellular 
matrix. In: Cell Biology, Philadelphia, Saunders Elsevier, pp 513-598. 
Refaat, M.; Chemaly, E.; Lebeche, D.; Gwathmey, J.K. & Hajjar, R.J. (2008). Ventricular 
arrhythmias after left ventricular assist device implantation. Pacing Clin 
Electrophysiol  31(10), 1246-1252. 
Schipper, M.E.; van Kuik, J.; de Jonge, N.; Dullens, H.F. & De Weger, R.A. (2008). Changes in 
regulatory microRNA expression in myocardium of heart failure patients on left 
ventricular assist device support. J Heart Lung Transplant  27(12), 1282-1285. 
Schuldt, A. (2010). Great expectations of small RNAs. Nature Revs Mol Cell Biol 11, 27. 
Seok, H.Y. & Wang, D.Z. (2010). The emerging role of microRNAs as a therapeutic target for 
cardiovascular disease. Biodrugs 24(3), 147-155. 
Spinale, F.G. (2002). Matrix metalloproteinases: regulation and dysregulation in the failing 
heart. Circ Res  90(4), 520-530. 
Stamenkovic, I. (2003). Extracellular matrix remodelling: the role of matrix 
metalloproteinases. J Pathol  200(4), 448-464. 
Thohan, V.; Stetson, S.J.; Nagueh, S.F.; Rivas-Gotz, C.; Koerner, M.M.; Lafuente, J.A.; Loebe, 
M.; Noon, G.P. & Torre-Amione, G. (2005). Cellular and hemodynamics responses 
of failing myocardium to continuous flow mechanical circulatory support using the 
DeBakey-Noon left ventricular assist device: A comparative analysis with pulsatile-
type devices. J Heart Lung Transplant 24(5), 566-575. 
Townley-Tilson, W.H.D.; Callis, T.E. & Wang, D.Z. (2010).  MicroRNAs 1, 133, and 206: 
Critical factors of skeletal and cardiac muscle development, function and disease. 
Int. J. Biochem. Cell Biol 42 (8), 1252-1255. 
Uray, I.P.; Connelly, J.H. & Frazier, O.H.; Taegtmeyer, H. & Davies, P.J. (2003).  Mechanical 
unloading increases caveolin expression in the failing human heart. Cardiovasc Res 
59(1), 57-66. 
Van Rooij, E.; Sutherland, L.B.; Liu, N.; Williams, A.H.; McAnally, J.; Gerard, R.D.; 
Richardson, J.A. & Olson, E.N. (2006). A signature pattern of stress responsive 
microRNAs that can evoke cardiac hypertrophy and heart failure. Proc Natl Acad 
Sci USA 103(48), 18255-60. 
Vatta, M,; Stetson, S.J.; Jimenez, S.; Entman, M.L.; Noon, G.P.; Bowles, N.E.; Towbin, J.A. & 
Torre-Amione, G. (2004). Molecular normalization of dystrophin in the failing left 
and right ventricle of patients treated with either pulsatile or continuous flow-type 
ventricular assist devices . J Am Coll Cardiol 43(3), 811-817. 
www.intechopen.com
Ventricular Assist Devices
Edited by Dr. jeffrey Shuhaiber
ISBN 978-953-307-164-0
Hard cover, 212 pages
Publisher InTech
Published online 26, April, 2011
Published in print edition April, 2011
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
The assist devices will continue adding a large number of years of life to humans globally and empower the
medical society to optimize heart failure therapy. While expensive and cumbersome task, the foundation
provided in this book reflects a contemporary product of original research from a multitude of different experts
in the field. We hope this cumulative international effort provides the necessary tools for both the novice as
well as the active practitioner aiming to change the outcome of these complex patients.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Margue ́rite E.I. Schipper, Sjoukje I. Lok, Hub Dullens, Joyce Van Kuik, Frits H.J. Gmelig-Meyling, Jaap Lahpor,
Marc A. Vos, Arnoud Van Der Laarse, Nicolaas De Jonge, Matthijs F.M. Van Oosterhout and Roel A. De
Weger (2011). Altered Expression of mRNA and miRNA during Mechanical Support of the Failing Human
Heart, Ventricular Assist Devices, Dr. jeffrey Shuhaiber (Ed.), ISBN: 978-953-307-164-0, InTech, Available
from: http://www.intechopen.com/books/ventricular-assist-devices/altered-expression-of-mrna-and-mirna-
during-mechanical-support-of-the-failing-human-heart
© 2011 The Author(s). Licensee IntechOpen. This chapter is distributed
under the terms of the Creative Commons Attribution-NonCommercial-
ShareAlike-3.0 License, which permits use, distribution and reproduction for
non-commercial purposes, provided the original is properly cited and
derivative works building on this content are distributed under the same
license.
